Higher cost to Medicare for use of brand-name combo drugs instead of generic components

(JAMA Network) Brand-name combination drugs can be more expensive than the sum of their parts, especially when generic components are available. An analysis of Medicare Part D spending suggests $925 million is the difference between what Medicare reported spending in 2016 for 29 brand-name combination drugs and what the estimated spending would have been if generic components had been used for the same number of doses.

from EurekAlert! - Social and Behavioral Science https://ift.tt/2nXlGPW